Toll-like receptor polymorphisms and age-related macular degeneration

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 4, 2008, Pages 1652-1659

  Edwards, Albert O ^a   Chen, Dequan ^a   Fridley, Brooke L ^a   James, Katherine M ^a   Wu, Yanhong ^a   Abecasis, Goncalo ^b   Swaroop, Anand ^b,c,d   Othman, Mohammad ^b,c   Branham, Kari ^b,c   Iyengar, Sudha K ^e,f   Sivakumaran, Theru A ^e   Klein, Ronald ^g   Klein, Barbara E K ^g   Tosakulwong, Nirubol ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d NATIONAL EYE INSTITUTE   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

^f CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR;

ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; GENETIC ASSOCIATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; ADULT; AGED; BIOLOGICAL MODEL; DNA SEQUENCE; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENETICS; GENOTYPE; MIDDLE AGED; RETINA MACULA DEGENERATION; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; MACULAR DEGENERATION; MIDDLE AGED; MODELS, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SEQUENCE ANALYSIS, DNA; TOLL-LIKE RECEPTORS; VARIATION (GENETICS);

EID: 45549091151     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.07-1378     Document Type: Article

References (66)

1. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age- related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564-572.
2. Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science. 2005;308:421-424.
3. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308:419-421.
4. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308:385-389.
5. Jakobsdottir J, Conley YP, Weeks DE, Mali TS, Ferrell RE, Gorin MB. Susceptibility genes for age-related maculopathy on chromosome 10q26. Am J Hum Genet. 2005;77:389-407.
6. Rivera A, Fisher SA, Fritsche LG, et al. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet. 2005;14:3227-3236.
7. Gold B, Merriam JE, Zernant J, et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age- related macular degeneration. Nat Genet. 2006;38:458-462.
8. Goverdhan SV, Howell MW, Mullins RF, et al. Association of HLA class I and class II polymorphisms with age-related macular degeneration. Invest Ophthalmol Vis Sci. 2005;46:1726-1734.
9. Klaver CC, Kliffen M, van Duijn CM, et al. Genetic association of apolipoprotein E with age-related macular degeneration [published correction in Am J Hum Genet. 1998;63(4):1252]. Am J Hum Genet. 1998;63:200 -206.
10. Souied EH, Benlian P, Amouyel P, et al. The epsilon4 allele of the apolipoprotein E gene as a potential protective factor for exudative age-related macular degeneration. Am J Ophthalmol. 1998;125:353-359.
11. Zareparsi S, Buraczynska M, Branham KE, et al. Toll-like receptor 4 variant D299G is associated with susceptibility to age-related mac- ular degeneration. Hum Mol Genet. 2005;14:1449-1455.
12. Edwards AO, Malek G. Molecular genetics of AMD and current animal models. Angiogenesis 2007;10;119-132.
13. Yates JR, Sepp T, Matharu BK, et al. Complement C3 variant and the risk of age-related macular degeneration. N Engl JMed. 2007;357:553-561.
14. Kohl J. The role of complement in danger sensing and transmission. Immunol Res. 2006;34:157-176.
15. Parker LC, Prince LR, Sabroe I. Translational Mini-Review Series on Toll-like Receptors: networks regulated by toll-like receptors mediate innate and adaptive immunity. Clin ExpImmunol. 2007;147:199 -207.
16. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homo- logue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388:394 -397.
17. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998;282:2085-2088.
18. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413:732-738.
19. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004;303:1526-1529.
20. Diebold SS, Kaisho T, Hemmi H, Akira S, Reise Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 2004;303:1529 -1531.
21. Kindzelskii AL, Elner VM, Elner SG, Yang D, Hughes BA, Petty HR. Toll-like receptor 4 (TLR4) of retinal pigment epithelial cells participates in transmembrane signaling in response to photoreceptor outer segments. J Gen Physiol. 2004;124:139-149.
22. Klein ML, Schultz DW, Edwards A, et al. Age-related macular degeneration: clinical features in a large family and linkage to chromosome 1q. Arch Ophthalmol. 1998;116:1082-1088.
23. Majewski J, Schultz DW, Weleber RG, et al. Age-related macular degeneration: a genome scan in extended families. Am J Hum Genet. 2003;73:540 -550.
24. Thompson CL, Jun G, Klein BE, et al. Genetics of pigment changes and geographic atrophy. Invest Ophthalmol Vis Sci. 2007;48:3005-3013.
25. Iyengar SK, Song D, Klein BE, et al. Dissection of genomewide-scan data in extended families reveals a major locus and oligogenic susceptibility for age-related macular degeneration. Am J Hum Genet. 2004;74:20 -39.
26. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263-265.
27. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet. 2002;70:425-434.
28. Epstein MP, Satten GA. Inference on haplotype effects in case- control studies using unphased genotype data. Am JHum Genet. 2003;73:1316-1329.
29. Duncan RD, Epstein MP, Satten GA. Case-control haplotype inference (CHAPLIN), version 1.2, September 2006, http://www.genetics.emory.edu/labs/ epstein/software/chaplin/index.html.
30. Despriet DD, Klaver CC, Witteman JC, et al. Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. JAMA. 2006;296:301-309.
31. Gordon S. Pattern recognition receptors: doubling up for the innate immune response. Cell. 2002;111:927-930.
32. Kariko K, Ni H, Capodici J, Lamphier M, Weissman D. mRNA is an endogenous ligand for toll-like receptor 3. JBiol Chem. 2004;279:12542-12550.
33. Lau CM, Broughton C, Tabor AS, et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/toll-like receptor 7 engagement. J Exp Med. 2005;202:1171-1177.
34. Ronnefarth VM, Erbacher AI, Lamkemeyer T, et al. TLR2/TLR4-independent neutrophil activation and recruitment upon endo-cytosis of nucleosomes reveals a new pathway of innate immunity in systemic lupus erythematosus. J Immunol. 2006;177:7740-7749.
35. Li M, Carpio DF, Zheng Y, et al. An essential role of the NF-kappa B/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J Immunol. 2001; 166:7128-7135.
36. Hoffman RW, Gazitt T, Foecking MF, et al. U1 RNA induces innate immunity signaling. Arthritis Rheum. 2004;50:2891-2896.
37. Kelly KM, Zhuang H, Nacionales DC, et al. "Endogenous adjuvant" activity of the RNA components of lupus autoantigens Sm/RNP and Ro 60. Arthritis Rheum. 2006;54:1557-1567.
38. Bell JK, Botos I, Hall PR, et al. The molecular structure of the toll-like receptor 3 ligand-binding domain. Proc Natl Acad Sci USA. 2005;102:10976-10980.
39. Sun J, Duffy KE, Ranjith-Kumar CT, et al. Structural and functional analyses of the human toll-like receptor 3. Role of glycosylation. J Biol Chem. 2006;281:11144-11151.
40. Choe J, Kelker MS, Wilson IA. Crystal structure of human toll-like receptor 3 (TLR3) ectodomain. Science. 2005;309:581-585.
41. Ranjith-Kumar CT, Miller W, Xiong J, et al. Biochemical and functional analyses of the human toll-like receptor 3 ectodomain. J Biol Chem. 2007;282:7668-7688.
42. de Bouteiller O, Merck E, Hasan UA, et al. Recognition of double- stranded RNA by human toll-like receptor 3 and downstream receptor signaling requires multimerization and an acidic pH. J Biol Chem. 2005;280:38133-38145.
43. Kumar MV, Nagineni CN, Chin MS, Hooks JJ, Detrick B. Innate immunity in the retina: toll-like receptor (TLR) signaling in human retinal pigment epithelial cells. J Neuroimmunol. 2004;153:7-15.
44. Elner SG, Petty HR, Elner VM, et al. TLR4 mediates human retinal pigment epithelial endotoxin binding and cytokine expression. Invest Ophthalmol Vis Sci. 2005;46:4627- 4633.
45. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res. 2001;20:705-732.
46. Prehaud C, Megret F, Lafage M, Lafon M. Virus infection switches TLR-3-positive human neurons to become strong producers of beta interferon. J Virol. 2005;79:12893-12904.
47. Penfold PL, Killingsworth MC, Sarks SH. Senile macular degeneration: the involvement of immunocompetent cells. Graefes Arch Clin Exp Ophthalmol. 1985;223:69 -76.
48. Tsutsumi C, Sonoda KH, Egashira K, et al. The critical role of ocular-infiltrating macrophages in the development of choroidal neovascularization. J Leukoc Biol. 2003;74:25-32.
49. Ambati J, Anand A, Fernandez S, et al. An animal model of age- related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. Nat Med. 2003;9:1390-1397.
50. Forrester JV, Lumsden L, Duncan L, Dick AD. Choroidal dendritic cells require activation to present antigen and resident choroidal macrophages potentiate this response. Br J Ophthalmol. 2005;89:369-377.
51. Lee MT, Hooper LC, Kump L, et al. Interferon-beta and adhesion molecules (E-selectin and s-intracellular adhesion molecule-1) are detected in sera from patients with retinal vasculitis and are induced in retinal vascular endothelial cells by Toll-like receptor 3 signalling. Clin Exp Immunol. 2007;147:71-80.
52. Pawar RD, Patole PS, Ellwart A, et al. Ligands to nucleic acid- specific toll-like receptors and the onset of lupus nephritis. J Am Soc Nephrol. 2006;17:3365-3373.
53. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991-1045.
54. Newsome DA, Hewitt AT, Huh W, Robey PG, Hassell JR. Detection of specific extracellular matrix molecules in drusen, Bruch's membrane, and ciliary body. Am J Ophthalmol. 1987; 104:373-381.
55. Kliffen M, Mooy CM, Luider TM, Huijmans JG, Kerkvliet S, de Jong PT. Identification of glycosaminoglycans in age-related macular deposits. Arch Ophthalmol. 1996;114:1009-1014.
56. Mullins RF, Russell SR, Anderson DH, Hageman GS. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J. 2000;14:835- 846.
57. Johnson LV, Leitner WP, Staples MK, Anderson DH. Complement activation and inflammatory processes in drusen formation and age related macular degeneration. Exp Eye Res. 2001; 73:887-896.
58. Crabb JW, Miyagi M, Gu X, et al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci USA. 2002;99:14682-14687.
59. Gu X, Meer SG, Miyagi M, et al. Carboxxyethylpyrrole protein adducts and autoantibodies' biomarkers for age-related macular degeneration. J Biol Chem. 2003;278:42027-42035.
60. Mullins RF, Aptsiauri N, Hageman GS. Structure and composition of drusen associated with glomerulonephritis: implications for the role of complement activation in drusen biogenesis. Eye. 2001;15: 390-395.
61. Espinosa-Heidmann DG, Suner IJ, Catanuto P, Hernandez EP, Marin-Castano ME, Cousins SW. Cigarette smoke-related oxidants and the development of sub-RPE deposits in an experimental animal model of dry AMD. Invest Ophthalmol Vis Sci. 2006;47: 729-737.
62. Kilingsworth MC, Sarks JP, Sarks SH. Macrophages related to Bruch's membrane in age-related macular degeneration. Eye. 1990;4:613-621.
63. Tahara K, Kim HD, Jin JJ, Maxwell JA Li L, Fukuchi K. Role of toll-like receptor signalling in Abeta uptake and clearance. Brain. 2006;129:3006-3019.
64. Johnson PT, Betts KE, RRadeke MJ, Hageman GS, Anderson DH Johnson LV. Individuals homozygous for the age-related macular degeneration risk-conferring variant of complement factor H have elevated levels of CRP in the choroid. Proc Natl Acad Sci USA. 2006;103:17456-17461.
65. Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol. 2002;134:411-431.
66. Lang KS, Georgiev P, Recher M' et al. Immunoprivileged status of the liver is controlled by toll-like receptor 3 signaling. JClin Invest. 2006;116:2456-2463.